This newsletter presents you the following key sessions:
1. Adding sugemalimab to first-line chemotherapy improves the survival of patients with advanced
oesophageal squamous cell carcinoma
2. Survival benefit and maintained quality of life with trifluridine/tipiracil-bevacizumab in refractory
metastatic colorectal cancer
3. Pembrolizumab extends benefit in subsequent therapies of HER2-negative gastric or gastro-
oesophageal junction adenocarcinoma
4. Favourable benefit-risk profile for ivosidenib compared to placebo in patients with IDH1-mutated
intrahepatic cholangiocarcinoma